IN192520B - - Google Patents

Info

Publication number
IN192520B
IN192520B IN823DE2001A IN192520B IN 192520 B IN192520 B IN 192520B IN 823DE2001 A IN823DE2001 A IN 823DE2001A IN 192520 B IN192520 B IN 192520B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Maitra Amarnath
Mozumdar Subho
Mitra Susmita
Roy Indrajit
Original Assignee
Univ Delhi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Delhi filed Critical Univ Delhi
Priority to IN823DE2001 priority Critical patent/IN192520B/en
Priority to US10/201,247 priority patent/US6555376B2/en
Publication of IN192520B publication Critical patent/IN192520B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Inorganic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN823DE2001 2001-08-01 2001-08-01 IN192520B (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN823DE2001 IN192520B (pt) 2001-08-01 2001-08-01
US10/201,247 US6555376B2 (en) 2001-08-01 2002-07-24 Process of entrapping genetic materials in ultra-low size nanoparticles of inorganic compounds to form non-viral carriers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN823DE2001 IN192520B (pt) 2001-08-01 2001-08-01

Publications (1)

Publication Number Publication Date
IN192520B true IN192520B (pt) 2004-04-24

Family

ID=11097096

Family Applications (1)

Application Number Title Priority Date Filing Date
IN823DE2001 IN192520B (pt) 2001-08-01 2001-08-01

Country Status (2)

Country Link
US (1) US6555376B2 (pt)
IN (1) IN192520B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003103011A1 (en) * 2002-06-04 2003-12-11 Koninklijke Philips Electronics N.V. Low-pressure mercury vapor discharge lamp and compact fluorescent lamp
US20060166249A1 (en) * 2003-05-16 2006-07-27 University Of Rochester Methods for separating short single-stranded nucleic acid from long single-and double-stranded nucleic acid, and associated biomolecular assays
US8071132B2 (en) * 2004-06-01 2011-12-06 The Penn State Research Foundation Unagglomerated core/shell nanocomposite particles
WO2005123142A1 (en) * 2004-06-10 2005-12-29 Abraxis Bioscience, Inc. A method using inorganic nanoparticles as non-viral vectors for gene therapy
US7541028B2 (en) * 2005-01-04 2009-06-02 Gp Medical, Inc. Nanoparticles for monoclonal antibody delivery
JP2008527999A (ja) * 2005-01-21 2008-07-31 ユニバーシティー オブ ロチェスター 長い１本鎖核酸および２本鎖核酸から短い１本鎖核酸を分離するための方法、ならびに関連した生体分子アッセイ法
JP2010502362A (ja) * 2006-09-06 2010-01-28 ボストン サイエンティフィック リミテッド 巨大分子を送達するためのナノ構造コーティングを有する医療器具
US20080299182A1 (en) * 2007-03-01 2008-12-04 Shuyuan Zhang Methods and formulations for topical gene therapy
US20080241256A1 (en) * 2007-03-30 2008-10-02 Liisa Kuhn Targeted active agent delivery system based on calcium phosphate nanoparticles
MX2010008168A (es) 2008-01-25 2011-02-24 P53 Inc Biomarcadores p53.
US9937128B2 (en) 2009-08-03 2018-04-10 The University Of North Carolina At Chapel Hill Liposomes comprising a calcium phosphate-containing precipitate
US20130071326A1 (en) * 2010-03-17 2013-03-21 Board Of Regents Of The University Of Texas System Universal cell-directed theranostics
GB2489714B (en) 2011-04-05 2013-11-06 Tracesa Ltd Fluid Identification Method
BR112015002287A2 (pt) * 2012-07-31 2017-07-04 Joaquin Lopez processo para obtenção e detecção de um marcador de objetos a serem identificados, o marcador, método para autenticação e método para verificação
EP2953646B1 (en) * 2013-02-05 2021-03-10 1Globe Health Institute LLC Biodegradable and clinically-compatible nanoparticles as drug delivery carriers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266205A (en) * 1988-02-04 1993-11-30 Battelle Memorial Institute Supercritical fluid reverse micelle separation
DE60013773T2 (de) * 1999-02-03 2005-11-10 Biosante Pharmaceuticals, Inc. Methoden zur Herstellung von therapeutischen Kalziumphosphat Partikeln

Also Published As

Publication number Publication date
US20030027336A1 (en) 2003-02-06
US6555376B2 (en) 2003-04-29

Similar Documents

Publication Publication Date Title
BE2022C531I2 (pt)
BE2022C502I2 (pt)
BE2022C547I2 (pt)
BE2017C057I2 (pt)
BE2017C051I2 (pt)
BE2017C032I2 (pt)
BE2016C051I2 (pt)
BE2015C046I2 (pt)
BE2014C052I2 (pt)
BE2014C036I2 (pt)
BE2014C026I2 (pt)
BE2014C004I2 (pt)
BE2014C006I2 (pt)
BE2017C050I2 (pt)
BE2011C034I2 (pt)
BE2007C047I2 (pt)
AU2002307149A8 (pt)
BRPI0209186B1 (pt)
BE2014C008I2 (pt)
BRPI0204884B1 (pt)
CH1379220H1 (pt)
BE2016C021I2 (pt)
BE2017C059I2 (pt)
BRPI0101486B8 (pt)
BE2012C051I2 (pt)